Longitudinally cultured precision cut lung slices as a predictive ex vivo model for metastatic lung cancer

AIM: platform for lung cancer research. We established the prolonged viability and structural preservation of PCLS, essential for accurate drug response studies. MATERIAL AND METHODS: Using Paclitaxel as a benchmark drug and a therapeutically promising silver nanoparticles in combination with immunotherapy, we conducted a pioneering comparative analysis of its therapeutic effects on PCLS against traditional in vivo models. RESULTS: responses, demonstrating comparable drug efficacy in tumor growth inhibition. CONCLUSION: This direct comparison not only confirms the utility of PCLS in simulating real-world outcomes but also emphasizes its potential in reducing animal testing. By providing a reliable, ethical, and efficient alternative for lung cancer studies, PCLS could significantly enhance preclinical research and drug development, marking a critical step toward more humane and representative scientific investigations.